NKGen Biotech, Inc.
NKGNDelisted Jul 17, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001845459
NKGen Biotech, Inc. was delisted on Jul 17, 2025; its insiders filed their last Form 4 on Jun 2, 2025; no institution reported holding it in 13F filings for Q2 2025; no superinvestor held it.
Key figures
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 0
- Q2 2025, −3 vs. previous quarter
- 13F value
- $0
- Reported value at the end of Q2 2025
- Superinvestors holding
- 0
- At the end of Q2 2025
Superinvestors holding NKGN, Q2 2025
No superinvestor reported holding NKGN at the end of Q2 2025.
Latest insider trades
Open-market purchases and sales by NKGen Biotech, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jun 2, 2025 (view filing)12:11 PM ET | May 27 | 6 daysLate | Cherng Peggy and 2 others10% Owner | PPurchase | +19.7M | $0.1271 | +$2.50M | +944.1%21.8M after | |
| Jun 2, 2025 (view filing)12:11 PM ET | May 27 | 6 daysLate | Cherng Peggy and 2 others10% Owner | PPurchase | +39.3M | $0.1271 | +$5.00M | –39.3M after | Derivative |
| May 7, 2025 (view filing)4:05 PM ET | May 5 | 2 days | Song Paul Y.Chief Executive Officer | PPurchase | +20.8M | $0.1271 | +$2.65M | +12,184.2%21.0M after | |
| May 7, 2025 (view filing)4:05 PM ET | May 5 | 2 days | Song Paul Y.Chief Executive Officer | PPurchase | +41.7M | $0.1271 | +$5.30M | –41.7M after | Derivative |
| Dec 7, 2023 (view filing) | Dec 6-7 | 1 day | Song Paul Y.Chief Executive Officer | PPurchase | +151.36 | $3.30 | +$500.24 | +0.1%171.1K after | 2 lots |
| Dec 5, 2023 (view filing)3:50 PM ET | Dec 1-4 | 4 days | Graf James A and 1 otherInterim CFO | PPurchase | +670 | $3.24 | +$2.17K | +2,913.0%693 after | 2 lots |
| Dec 5, 2023 (view filing) | Dec 4-5 | 1 day | Song Paul Y.Chief Executive Officer | PPurchase | +267.95 | $3.17 | +$849.95 | +0.2%171.0K after | 2 lots |
| Nov 28, 2023 (view filing) | Nov 27 | 1 day | Song Paul Y.Chief Executive Officer | PPurchase | +243.65 | $2.88 | +$700.6 | +0.1%170.7K after | 2 lots |
| Nov 22, 2023 (view filing)5:55 PM ET | Nov 20-21 | 2 days | Graf James A and 1 otherInterim CFO | PPurchase | +23 | $2.93 | +$67.3 | New position23 after | 2 lots |
| Nov 22, 2023 (view filing) | Nov 21-22 | 1 day | Song Paul Y.Chief Executive Officer | PPurchase | +152.63 | $2.82 | +$430 | +0.1%170.5K after | 2 lots |
Top 10 13F holders, Q2 2025
The largest institutional positions in NKGen Biotech, Inc. at the end of Q2 2025; share changes are against Q1 2025.
No institution reported holding NKGN in 13F filings for Q2 2025.
Holders of 5% or more of NKGN
Holders whose latest Schedule 13D or 13G filing reports 5% or more of NKGen Biotech, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Song Paul Y. | 13D | 54.30%63.7M shares | New | May 12, 20251 filing | May 12, 2025 | SEC |
| CFIC-2015 NV Family Investments, LLC | 13D | 47.20%63.2M shares | – | Aug 22, 20242 filings | Jun 2, 2025 | SEC |
| Pathstone Family Office, LLC | 13G | 7.91%2.80M shares | New | Feb 28, 20251 filing | Feb 28, 2025 | SEC |
| Meteora Capital, LLC | 13G/A | 6.13%2.76M shares | −1.71 ppfrom 7.84% | Feb 14, 20244 filings | May 15, 2025 | SEC |